高橋 雅道 たかはし まさみち 先生

来歴等

略歴

2001年 東京大学医学部附属病院　脳神経外科
2002年 亀田総合病院　脳神経外科
2003年 東京都立駒込病院　脳神経外科
2006年 東京大学医学部附属病院　脳神経外科
2006年 国立がんセンター中央病院　脳神経外科
2007年 東京大学大学院医学系研究科 入学
2011年 東京大学大学院医学系研究科 博士（医学） 卒業
2011年 カリフォルニア大学ロサンゼルス校（UCLA） 留学
2014年 国立がん研究センター中央病院　脳脊髄腫瘍科 医員
2020年 国立がん研究センター中央病院　脳脊髄腫瘍科 医長
2024年 東海大学脳神経外科 教授
2024年 東海大学医学部付属病院 脳神経外科 領域主任・診療科長

論文

• Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 2019;110(7):2247-57.

  Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, et al.

• First case of human neurocoenurosis caused by Taenia serialis: A case report. Int J Infect Dis. 2020;92:171-4.

  Yamazawa E, Ohno M, Satomi K, Yoshida A, Miyakita Y, Takahashi M, et al.

• Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Jpn J Clin Oncol. 2020.

  Tanaka S, Sato I, Takahashi M, Armstrong TS, Cleeland CS, Mendoza TR, et al.

• Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma. Jpn J Clin Oncol. 2020.

  Miyakita Y, Ohno M, Takahashi M, Kurihara H, Katai H, Narita Y.

• Frequent false-negative immunohistochemical staining with IDH1 (R132H)-specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis. Histopathology. 2019;74(2):350-4.

  Yoshida A, Satomi K, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, et al.

• A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma. Surg Neurol Int. 2019;10:256.

  Yamazawa E, Honma Y, Satomi K, Taniguchi H, Takahashi M, Yoshida A, et al.

• Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged >/= 75 years. Radiat Oncol. 2019;14(1):200.

  Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K, et al.

• Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma. JAMA Netw Open. 2019;2(12):e1916953.

  Ohno M, Matsuzaki J, Kawauchi J, Aoki Y, Miura J, Takizawa S, et al.

• Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network. Sci Rep. 2019;9(1):20311.

  Fukuma R, Yanagisawa T, Kinoshita M, Shinozaki T, Arita H, Kawaguchi A, et al.

• Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathol. 2018;35(3):148-58.

  Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, et al.

• Clinical outcomes of brain metastases from hepatocellular carcinoma: a multicenter retrospective study and a literature review. Int J Clin Oncol. 2018;23(6):1095-100.

  Okuda T, Hayashi N, Takahashi M, Uzuka T, Okita Y, Otani R, et al.

• Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. Cancer Sci. 2018;109(7):2275-85.

  Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, et al.

• Cryptococcus gattii genotype VGIIa infection imported from Vancouver Island to Japan. J Infect Chemother. 2018;24(7):573-5.

  Kitaura T, Takahashi M, Umeyama T, Takeshita N, Katanami Y, Takaya S, et al.

• Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Therapy. 2018.

  Inoko K, Hiraoka K, Inagaki A, Takahashi M, Kushibiki T, Hontani K, et al.

• Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018;6(1):134.

  Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D, et al.

• Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas. Sci Rep. 2018;8(1):11773.

  Arita H, Kinoshita M, Kawaguchi A, Takahashi M, Narita Y, Terakawa Y, et al.

• Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017.

  Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, et al.

• Detection Method for Aquatic Bacteria of the Fingers, as a Potential Origin of the Aqueous Solution Contamination. Biocontrol Sci. 2017;22(1):61-5.

  Osono E, Honda K, Inoue Y, Norose Y, Takahashi M, Ichimura K, et al.

• Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). Jpn J Clin Oncol. 2017;47(10):919-24.

  Miyakita Y, Ohno M, Takahashi M, Muragaki Y, Katai H, Narita Y.

• Outcomes of surgery followed by local brain radiotherapy compared with surgery followed by whole brain radiotherapy for single brain metastasis. Tumori. 2017;103(4):367-73.

  Igaki H, Harada K, Umezawa R, Miyakita Y, Ohno M, Takahashi M, et al.

• Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol. 2017.

  Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, et al.

• A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer. BMC Cancer. 2017;17(1):397.

  Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, et al.

• Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathol Commun. 2017;5(1):18.

  Aihara K, Mukasa A, Nagae G, Nomura M, Yamamoto S, Ueda H, et al.

• Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. Mol Clin Oncol. 2016;5(3):179-85.

  Okita Y, Narita Y, Miyakita Y, Miyahara R, Ohno M, Takahashi M, et al.

• Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Ther. 2014;21(10):405-10.

  Takahashi M, Valdes G, Hiraoka K, Inagaki A, Kamijima S, Micewicz E, et al.

• Epithelial Membrane Protein-2 ( EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma. J Biol Chem. 2014;289(20):13974-85.

  Qin Y, Fu MY, Takahashi M, Iwanami A, Kuga D, Rao RG, et al.

• Rapid detection of microbes in the dialysis solution by the microcolony fluorescence staining method (Millflex quantum). Biocontrol Sci. 2014;19(1):57-60.

  Osono E, Kobayashi E, Inoue Y, Honda K, Kumagai T, Negishi H, et al.

• Combined Alloreactive CTL Cellular Therapy with Prodrug Activator Gene Therapy in a Model of Breast Cancer Metastatic to the Brain. Clin Cancer Res. 2013;19(15):4137-48.

  Hickey MJ, Malone CC, Erickson KL, Lin A, Soto H, Ha ET, et al.

• Complete genome sequence of Sphingobium sp. strain SYK-6, a degrader of lignin-derived biaryls and monoaryls. J Bacteriol. 2012;194(2):534-5.

  Masai E, Kamimura N, Kasai D, Oguchi A, Ankai A, Fukui S, et al.

• Glioma-initiating Cells Retain Their Tumorigenicity through Integration of the Sox Axis and Oct4 Protein. J Biol Chem. 2011;286(48):41434-41.

  Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, et al.

• THIRD GENERATION ONCOLYTIC HSV-1 (G47 Delta) IS HIGHLY EFFICACIOUS FOR MALIGNANT PLEURAL MESOTHELIOMA. J Gene Med. 2010;12(12):1032-3.

  Takahashi M, Ino Y, Todo T.

• Combined movement of multi-joint muscles activates a smaller area compared to the sum of areas activated by respective single-joint muscles after restoration of paresis. Neurocase. 2010;16(2):175-81.

  Shinoura N, Suzuki Y, Yamada R, Tabei Y, Takahashi M, Yagi K.

• Autocrine TGF-beta Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors. Cell Stem Cell. 2009;5(5):504-14.

  Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K.

• Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J Neuro-Oncol. 2008;87(3):309-16.

  Shinoura N, Tabei Y, Yamada R, Saito K, Takahashi M.

• Navigation-guided Ommaya reservoir placement: Implications for the treatment of leptomeningeal metastases. Minim Invas Neurosur. 2007;50(6):340-5.

  Takahashi M, Yamada R, Tabei Y, Nakamura O, Shinoura N.

• Functional magnetic resonance imaging is more reliable than somatosensory evoked potential or mapping for the detection of the primary motor cortex in proximity to a tumor. Stereot Funct Neuros. 2007;85(2-3):99-105.

  Shinoura N, Yamada R, Suzuki Y, Kodama T, Sekiguchi K, Takahashi M, et al.

• Use of Tc-99 MIBI SPECT for characterization of metastatic brain tumors: Implications for surgery. Clin Nucl Med. 2006;31(9):538-40.

  Shinoura N, Yamada R, Takahashi M, Nakamura O.

• Delineation of brain tumor margins using intraoperative sononavigation: Implications for tumor resection. J Clin Ultrasound. 2006;34(4):177-83.

  Shinoura N, Takahashi M, Yamada R.

• Restored activation of primary motor area from motor reorganization and improved motor function after brain tumor resection. Am J Neuroradiol. 2006;27(6):1275-82.

  Shinoura N, Suzuki Y, Yamada R, Kodama T, Takahashi M, Yagi K.

• Intraoperative cortical mapping has low sensitivity for the detection of motor function in proximity to a tumor in the primary motor area. Stereot Funct Neuros. 2005;83(4):135-41.

  Shinoura N, Yamada R, Kodama T, Suzuki Y, Takahashi M, Yagi K.

• Preoperative fMRI, tractography and continuous task during awake surgery for maintenance of motor function following surgical resection of metastatic tumor spread to the primary motor area. Minim Invas Neurosur. 2005;48(2):85-90.

  Shinoura N, Yamada R, Kodama T, Suzuki Y, Takahashi M, Yagi K.

• Association of motor deficits with head position during awake surgery for resection of medial motor area brain tumors. Minim Invas Neurosur. 2005;48(6):315-21.

  Shinoura N, Yamada R, Kodama T, Suzuki Y, Takahashi M, Yagi K.

• Accurate characterization of the main trunk of the anterior cerebral artery by means of intraloperative sononavigation with Doppler sonography - Implications for brain tumor surgery. J Ultras Med. 2005;24(11):1527-32.

  Shinoura N, Takahashi M, Yamada R.

• Fibers connecting the primary motor and sensory areas play a role in grasp stability of the hand. Neuroimage. 2005;25(3):936-41.

  Shinoura N, Suzuki Y, Yamada R, Kodama T, Takahashi M, Yagi K.

• Coagulation-fibrinolysis parameters and platelet function at the onset of intracerebral hemorrhage in uremic patients. Neurosurg Emerg. 2004;9:60-4.

  Takahashi M, Hara T, Tamaki T, M. S, R. K, T. K, et al.

• 脳腫瘍における遺伝子治療の現状と研究動向. 東京: 技術情報協会; 2017 2017/4/28.

  高橋雅道.

• 脳腫瘍 Central Nervous System Tumors. In: 国立がん研究センター内科レジデント, editor. がん診療レジデントマニュアル　第7版. 7 ed. 東京: 医学書院; 2016. p. 339-48.

  佐藤潤, 高橋雅道.

• 治療方法の意義と合併症. In: 田村晃, 松谷雅生, 清水輝夫, 辻貞俊, 塩川芳昭, 成田善孝, editors. EBMに基づく脳神経疾患の基本治療指針. 4 ed. 東京: メジカルビュー社; 2016. p. 90-7.

  高橋雅道, 成田善孝.

• 【今、最も新しい手術室のかたち】 最先端手術室の必要性を問う　裸眼3Dディスプレイシステムによる脳腫瘍手術の実際および画像記録と再生の有用性. 新医療. 2016;43(4):80-4.

  高橋雅道, 成田善孝.

• 脳腫瘍術前術後管理におけるホスフェニトインの使用方法. In: 信和 中, editor. 神経救急・脳神経外科周術期におけるてんかん発作の管理　ホスフェニトインによる実践集. 東京: 式会社 ライフ・サイエンス; 2015. p. 165-9.

  高橋雅道, 成田善孝.

• 【婦人科がん診療を支えるトータルマネジメント-各領域のエキスパートに聞く】　他臓器転移への対策 脳転移. 臨床婦人科産科. 2015;69(12):1167-73.

  高橋雅道, 成田善孝.

受賞

• 1. 2008年 東京大学脳神経外科同門会賞（若手）

• 2. 2012年 第18回日本遺伝子治療学会 最優秀ポスター賞

• 3. 2018年 国立がん研究センター研究所長賞

• 4. 2019年 マンスフィールド-PhRMA研究者プログラムフェロー

• 5. 2020年 東京大学脳神経外科同門会賞（シニア）

SNS・ブログ等

• その他メディア
  • Japan Cancer Forum 2018 脳腫瘍　～脳腫瘍ってどんな病気？脳腫瘍になったらどうすればいいの？～